News | April 27, 2022
Syngene full-year revenue from operations up 19% to Rs. 2604 crore
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
It supports advanced research and helps scientists accelerate potential cures, drug discoveries and diagnostics research
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
Co–Founder Sam Santhosh steps down as Chairman and Group CEO; will remain on Board of Directors. Co–founder Mahesh Pratapneni appointed Group CEO. Dr. Felix Olale appointed Chairman of the Board
Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
Arum's research focuses on the discovery of new chemical entities that will act as effective therapies for drug-resistant cancers
New line of Waters MaxPeak Premier columns further enhances the analysis by delivering 2x to 3x greater sensitivity than conventional steel columns
The facility will produce 150 million vaccine doses per year
Subscribe To Our Newsletter & Stay Updated
